ASML Holding N.V. (ASML)
Verdict history · ASML
Every call Verdix has made on ASML.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call ASML yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Information Technology / Semiconductor Equipment · 2026-08-15 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitHIGH confidence
Why
Six investor frameworks examine ASML, the undisputed monopoly in EUV lithography, and reach a rare agreement: the business is extraordinary, the numbers are pristine, and the AI tailwind is real. Their split is not about the company but about the price. At 56x trailing earnings after a 115% year-to-date surge, five of six voices conclude the stock is too rich for new money and point to the same $1,500-$1,700 zone as the level where patience gets rewarded. The verdict lands at WAIT with high conviction, rooting the call in price discipline rather than any doubt about ASML's competitive position.Level to watch
Key support 1,696.99−8.0% from 1,844.08
Next catalyst
The zone where conviction flips: A pullback into $1,500-$1,700, which encompasses the weekly EMA50 (~$1,570), the weekly Fib 38.2% ($1,510), and the entry range cited by five of six archetypes, would turn this panel from a WAIT into a broad-based BUY, provided the fundamental story remains intact.The panel's take
Verdict: WAIT · Conviction: HIGH · Last price: 1844.08
Every voice — bull and bear alike — agrees ASML is a phenomenal monopoly with outstanding financials. The split is not BUY vs SELL (business disagreement); it is BUY-NOW vs BUY-LATER (price/timing). Bulls (The Scuttlebutt Growth Investor, The Disruptive-Innovation Seeker) explicitly say they'd prefer a pullback; neutrals (The Intrinsic-Value Modeler, The GARP Operator, The Quality Rationalist) cite 56x P/E as too rich for new money; the lone bear (The Forensic Skeptic) wants $900-1,100 but concedes the business is wonderful. Since every cautious voice objects on PRICE/TIMING — not on the business — and there is a specific price trigger ($1,500–$1,700 zone, cited by multiple voices as key support), the structure is a textbook BUY vs WAIT split. WAIT is the correct verdict, not BALANCED.
Key levels
Key levels · ASML
USD · as of 2026-08-15Analyst consensus target 1,844.08 USD · range 1,844.08–1,844.08
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran ASML Holding N.V. past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: ASML's 100% EUV monopoly and the AI-driven demand acceleration are undeniable, but the market has already priced in near-perfect execution: at 57x trailing earnings and 42x forward, the valuation multiple is what you assign to a hypergrowth software company with recurring revenue, not a cyclical capital-equipment business whose $1,550 DCF-derived fair value sits 16% below the current quote. Conviction: Conviction is tempered because the gap between price and fundamental reality leaves zero margin of safety for the geopolitical shocks, cyclical downturns, and execution risks that have historically produced 35%+ drawdowns in semiconductor equipment stocks.
The Disruptive-Innovation SeekerDisruptive Innovation🟢 BullishMed
Signal: ASML is the literal chokepoint of the AI revolution: every advanced AI accelerator, HBM stack, and autonomous-vehicle SoC passes through EUV lithography, and the company's own 2030 revenue framework of €44-60bn is already being dwarfed by independent models from Bernstein (€92bn) and BofA (€90bn), signaling a TAM expanding faster than management can publicly model. Conviction: What holds conviction back from maximum is the stock's 245% run from the April 2025 lows and the 56-58x trailing multiple, which mean the base-case 5-year CAGR of ~3.5% is modest; the real upside requires a pullback toward $1,500-1,700 to restore asymmetry.
The Scuttlebutt Growth InvestorGrowth/Management🟢 BullishHigh
Signal: ASML scores a perfect 15 out of 15 on the Scuttlebutt Growth Investor checklist, anchored by a monopoly moat with no substitute technology, a CEO who openly discusses risks while raising guidance toward €43-45bn for FY26, and order books extending into 2028 that confirm the kind of multi-year visibility only the truly exceptional growth companies ever generate. Conviction: Conviction is held in check by a single unresolved variable: the TTM P/E of 56-58x leaves no cushion if the broader AI capex cycle pauses, even though The Scuttlebutt Growth Investor's framework tolerates rich multiples for a business of this caliber held over a 5-10 year horizon.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: The PEG ratio sits at roughly 2.8, well above the 1.0 ceiling that separates investing from speculating in this framework, and the technical picture reinforces the caution: monthly RSI overbought, a fresh weekly MACD bearish cross, and thin volume at current levels all echo the warning that the easy money was made during the 115% year-to-date run. Conviction: Confidence in the neutral stance is reinforced by a rare alignment of factors: a stretched valuation, an overheated chart, and 83% analyst Buy ratings that together suggest the crowd arrived before the opportunity.
The Quality RationalistMental Models/Quality⚫ NeutralMed
Signal: The business is as close to a perfect monopoly as exists in global technology, with an ROE consistently above 50%, net margins near 30%, a net-cash balance sheet, and a moat so wide that it would take a competitor 20 years and $100 billion just to attempt a rival EUV system. Conviction: What keeps conviction firmly in neutral rather than bullish is the price tag: 56x earnings for even the best business in the world provides no margin of safety, and the monthly RSI overbought at 72 combined with price extended 46% above the monthly 20-EMA warns that a 30% correction could arrive long before the long-term compounding thesis pays off.
The Forensic SkepticContrarian/Forensic🔴 BearishMed
Signal: The consensus is suffocatingly bullish: 83% of analysts rate it a Buy, the stock is up 115% year-to-date, management's capacity expansion to 70% by 2028 is a massive bet placed at the top of an AI cycle, and the volume profile shows the stock floating in thin air with only 58 million shares accumulated in the $1,727-1,864 bin versus 627 million down at $636-772. Conviction: Conviction runs high on the bearish signal because the pattern is historically reliable: when every analyst loves a stock trading at 56x earnings with a fresh weekly MACD bearish cross, the next disappointment, whether it is a Q3 miss or a China export-control escalation, lands on a price that has no structural support beneath it.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- Every archetype agrees ASML holds a genuine, durable monopoly in EUV lithography with no credible near-term competitor and a 20-year head start.
- Every archetype agrees the financial quality is exceptional: 50%+ ROE, ~30% net margins, and a net-cash balance sheet.
- Every archetype agrees the AI-driven demand story is real and that lithography intensity is structurally rising.
- The five cautious voices (all except The Scuttlebutt Growth Investor) converge on the same price zone: $1,500-$1,700 is where the balance of upside to downside would flip constructive for new money.
- No archetype disputes that the stock is expensive on current multiples; even the bulls frame their case as 'great business, wait for a better price.'
The real debate
- The Scuttlebutt Growth Investor accepts a 56x multiple for a 15/15 checklist monopoly with multi-year visibility, while The Forensic Skeptic sees that same multiple as proof that the stock already discounts 2027 and 2028 orders, leaving no room for a single misstep.
- The Disruptive-Innovation Seeker treats management's conservative €44-60bn 2030 TAM framework as an upside catalyst because independent models point to €90bn+, whereas The Quality Rationalist warns that extrapolating recent order strength indefinitely is a classic recency-bias trap.
- The Intrinsic-Value Modeler anchors to a DCF-derived fair value of $1,550 with probability-weighted upside to $2,300 in the bull case, while The GARP Operator dismisses the whole setup as a PEG-ratio problem where the growth is real but the price paid for it crosses the line into speculation.
- The Forensic Skeptic flags the absence of free-cash-flow data in the fundamental analysis as a red flag and reads the capacity expansion as a double-edged bet made at a cyclical peak, a concern no other archetype raises with the same urgency.
The question it comes down to: At what price does ASML's undisputed monopoly moat and AI-driven demand visibility stop being a story you pay 56x earnings to hear and start being a compounding machine you can own with a genuine margin of safety?
The bottom line
- The zone where conviction flips: A pullback into $1,500-$1,700, which encompasses the weekly EMA50 (~$1,570), the weekly Fib 38.2% ($1,510), and the entry range cited by five of six archetypes, would turn this panel from a WAIT into a broad-based BUY, provided the fundamental story remains intact.
- The breakout to monitor: A weekly close above $2,000 with confirming volume resets the bearish MACD, validates the supercycle thesis, and would force even the valuation-conscious archetypes to revisit their base-case revenue and terminal-growth assumptions.
- The tripwire underneath: A weekly close below $1,510 snaps the trend structure that has supported the entire advance from the April 2025 lows and, combined with any fundamental deterioration (China controls, a Q3 miss, or customer deferrals), would open a path toward The Forensic Skeptic's $900-$1,100 fair-value range.
- Next catalyst: Q3 2026 earnings (guided to €11-12bn in sales with 55-57% gross margins) represent the first test of whether management can convert the raised bar into delivered results; a miss here would punish a stock priced for perfection far more than a beat would reward it.
contact@verdixhq.com · Published 2026-08-15 · Prices as of 2026-08-15 · Time horizon: 3–12 months · No direct position held in ASML · ASML verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated